PCM
FATE icon

Penserra Capital Management’s Fate Therapeutics FATE Stock Holding History

Penserra Capital Management’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-2,180
Closed -$129K – 1422
2021
Q3 		$129K Buy
2,180
+40
+2% +$3.14K ﹤0.01% 712
2021
Q2 		$185K Buy
2,140
+20
+0.9% +$1.61K ﹤0.01% 656
2021
Q1 		$174K Buy
2,120
+110
+5% +$10.5K ﹤0.01% 606
2020
Q4 		$182K Buy
2,010
+1,270
+172% +$78.9K ﹤0.01% 546
2020
Q3 		$29K Buy
+740
New +$25.8K ﹤0.01% 696

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Penserra Capital Management's FATE Position: Q4 2021 in Review

Penserra Capital Management sold out of Fate Therapeutics (FATE) in Q4 2021, closing a stake of 2,180 shares — an estimated $129K sold.

Penserra Capital Management first reported a position in FATE in Q3 2020 and held it in 5 quarters. The position peaked at $185K in Q2 2021. 250 funds tracked by Wall St. Rank hold FATE as of Q4 2021.

  • Penserra Capital Management reported no remaining Fate Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Penserra Capital Management sold 2,180 Fate Therapeutics shares in Q4 2021, an estimated $129K.
  • Penserra Capital Management first reported a position in Fate Therapeutics in Q3 2020 and held it in 5 quarters.
  • Penserra Capital Management's Fate Therapeutics position peaked at $185K in Q2 2021.
  • 250 funds tracked by Wall St. Rank held Fate Therapeutics as of Q4 2021.

Based on Penserra Capital Management's 13F filing for Q4 2021, filed 15 Feb 2022.